<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01178736</url>
  </required_header>
  <id_info>
    <org_study_id>WCF-2011-BRA-IND-CAM</org_study_id>
    <nct_id>NCT01178736</nct_id>
  </id_info>
  <brief_title>Early Detection of Cancers in Low Resource Countries</brief_title>
  <official_title>Efficacy of a Combined Program for Early Detection of Breast and Gynecological Cancers in Low Resource Countries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Woman's Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Woman's Cancer Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to implement a community-based combined program for early
      detection of breast, cervical, ovarian and endometrial cancer in low-resource countries
      delivered through a free standing or a mobile Well Woman Clinic. The goals of this program
      are to downstage cancers and improve mortality rates using low-cost early detection methods.
      These programs will be implemented in regions where early cancer detection strategies are not
      in place and cancers present at advanced stages with resultant high mortality. Currently,
      there are three target project sites: Cambodia (June 2011), India (June 2011), and Brazil
      (March 2011). Memorandums of Understanding have been secured with local health organizations
      in each region to establish clinic operations. Each clinic would serve an approximate target
      population of 100,000 amongst whom about 12,000 eligible women (4-5,000 annually) will be
      invited to be screened for breast and cervical cancer over a three-year time span.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will study the use of sonographic screening in addition to Clinical Breast Examination in
      low resource settings where screening programs are not currently in place and establishing a
      population based mammographic screening would be expensive, resource intensive, and difficult
      if not impossible to implement. The effectiveness of the screening and diagnostic methodology
      used for early detection of breast, cervical, ovarian and endometrial cancers in low resource
      settings will be studied. The program would involve screening of asymptomatic women for
      Breast and Cervical cancer and diagnostic assessment of symptomatic women for Ovarian and
      Endometrial cancer. Women in the age group of 30-59 yrs will be screened once every three
      years utilizing the following methods: Breast - clinical breast examination [CBE] and
      Sonography, followed by Fine needle aspiration biopsy (FNAB) of screen positive cases;
      Cervical - Human Papilloma Virus DNA testing followed by Cryotherapy of screen positive cases
      (Single visit, screen and treat approach); Ovarian - Transvaginal sonogram and clinical
      evaluation; Endometrial - Transvaginal sonographic assessment of the endometrial stripe.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The Effectiveness of an Innovative, Low-Cost Screening and Diagnostic Methodology</measure>
    <time_frame>Three (3) year interval</time_frame>
    <description>This study will examine the effectiveness of an innovative, low-cost screening and diagnostic methodology used for combined early detection of breast and gynecological cancers in low resource regions where early cancer detection strategies are not in place and cancers currently are diagnosed at advanced stages with resultant high mortality.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of CBE and Ultrasonography for Breast Cancer Detection</measure>
    <time_frame>Three (3) year interval</time_frame>
    <description>This study will examine the effectiveness of Clinical Breast Examination combined with Ultrasonography for breast cancer screening and detection in low resource settings where X-ray mammography proves not feasible in terms of cost, technology, and staff.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">36000</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Uterine Cervical Neoplasms</condition>
  <condition>Ovarian Neoplasms</condition>
  <condition>Endometrial Neoplasms</condition>
  <arm_group>
    <arm_group_label>Cancer Screening and Diagnosis</arm_group_label>
    <description>Screening of asymptomatic women for Breast and Cervical cancer in the age group of 35-64 years. Diagnostic assessment of symptomatic women for Ovarian and Endometrial cancer in the age group of 50-64 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Breast Cancer Screening and Diagnosis</intervention_name>
    <description>Clinical Breast Examination and Sonography followed by Fine needle aspiration biopsy (FNAB) of screen positive cases.</description>
    <arm_group_label>Cancer Screening and Diagnosis</arm_group_label>
    <other_name>FNAB</other_name>
    <other_name>CBE</other_name>
    <other_name>Ultrasound</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cervical Cancer Screening and Diagnosis</intervention_name>
    <description>Visual Inspection with Acetic acid, PAP smear or Human Papilloma Virus DNA testing followed by Cryotherapy of screen positive cases.</description>
    <arm_group_label>Cancer Screening and Diagnosis</arm_group_label>
    <other_name>HPV DNA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ovarian Cancer Screening and Diagnosis</intervention_name>
    <description>Transvaginal sonogram and clinical evaluation in post menopausal women with symptoms suggestive of ovarian cancer.</description>
    <arm_group_label>Cancer Screening and Diagnosis</arm_group_label>
    <other_name>Ultrasound</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endometrial Cancer Screening and Diagnosis</intervention_name>
    <description>Transvaginal sonographic assessment of the endometrial stripe in post menopausal women with abnormal bleeding.</description>
    <arm_group_label>Cancer Screening and Diagnosis</arm_group_label>
    <other_name>Ultrasound</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Brazil has two rural hospitals serving a population of roughly 46,000 people (Nova
        Andradina) inside Mato Grosso do Sul, which has a population of over 2 million. Cambodia
        has a population of over 1 million inside the Phnom Penh metropolitan area. India has a
        population of more than 1.3 million inside the state of Goa. According to the NFHS-2,
        nearly 30 percent of rural Goan women live 10 or more kilometers away from a primary health
        center.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Breast Cancer: women age 35-64

          -  Cervical Cancer: women age 30-59

          -  Ovarian Cancer: symptomatic post menopausal women age 50-64

          -  Endometrial Cancer: symptomatic post menopausal women age 50-64

        Exclusion Criteria:

          -  women under the age of 30
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weiwei Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center, University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diljeet K Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Feinberg School of Medicine, Northwestern University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adhemar Longatto Filho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paolo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Cancer de Barretos</name>
      <address>
        <city>Sao Paolo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edmundo Mauad, MD, PhD</last_name>
      <phone>(17) 3321-6600</phone>
      <email>ecmauad@hcancerbarretos.com.br</email>
    </contact>
    <investigator>
      <last_name>Edmundo Mauad, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sihanouk Hospital Center of Hope, Hope Worldwide Cambodia</name>
      <address>
        <city>Phnom Penh</city>
        <country>Cambodia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cornelia Haener, MD</last_name>
      <phone>(855-23) 882-484</phone>
      <email>corneliahaener@sihosp.org</email>
    </contact>
    <contact_backup>
      <last_name>Shelly Malhotra</last_name>
      <email>shellymalhotra@sihosp.org</email>
    </contact_backup>
    <investigator>
      <last_name>Cornelia Haener, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manipal Healthcare Group</name>
      <address>
        <city>Goa</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>R.G. Pinto, MD</last_name>
      <email>rgwpinto@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sharmila Sardesai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>R. G. Pinto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eugene D'Silva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Cambodia</country>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. JAMA. 2005 Mar 9;293(10):1245-56. Review.</citation>
    <PMID>15755947</PMID>
  </reference>
  <reference>
    <citation>Kuhl CK. The &quot;coming of age&quot; of nonmammographic screening for breast cancer. JAMA. 2008 May 14;299(18):2203-5. doi: 10.1001/jama.299.18.2203.</citation>
    <PMID>18477789</PMID>
  </reference>
  <reference>
    <citation>Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Böhm-Vélez M, Pisano ED, Jong RA, Evans WP, Morton MJ, Mahoney MC, Larsen LH, Barr RG, Farria DM, Marques HS, Boparai K; ACRIN 6666 Investigators. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA. 2008 May 14;299(18):2151-63. doi: 10.1001/jama.299.18.2151. Erratum in: JAMA. 2010 Apr 21;303(15):1482.</citation>
    <PMID>18477782</PMID>
  </reference>
  <reference>
    <citation>Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology. 2002 Oct;225(1):165-75.</citation>
    <PMID>12355001</PMID>
  </reference>
  <reference>
    <citation>Kaplan SS. Clinical utility of bilateral whole-breast US in the evaluation of women with dense breast tissue. Radiology. 2001 Dec;221(3):641-9.</citation>
    <PMID>11719658</PMID>
  </reference>
  <reference>
    <citation>Tohno E, Ueno E, Watanabe H. Ultrasound screening of breast cancer. Breast Cancer. 2009;16(1):18-22. doi: 10.1007/s12282-008-0082-8. Epub 2008 Nov 14.</citation>
    <PMID>19009372</PMID>
  </reference>
  <reference>
    <citation>Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA. HPV screening for cervical cancer in rural India. N Engl J Med. 2009 Apr 2;360(14):1385-94. doi: 10.1056/NEJMoa0808516.</citation>
    <PMID>19339719</PMID>
  </reference>
  <reference>
    <citation>Schiffman M, Wacholder S. From India to the world--a better way to prevent cervical cancer. N Engl J Med. 2009 Apr 2;360(14):1453-5. doi: 10.1056/NEJMe0901167.</citation>
    <PMID>19339726</PMID>
  </reference>
  <reference>
    <citation>Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA. 2001 Jun 27;285(24):3107-15. Erratum in: JAMA 2001 Sep 5;286(9):1026.</citation>
    <PMID>11427139</PMID>
  </reference>
  <reference>
    <citation>Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, Patras J, Mahony BS, Andersen MR. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007 Jan 15;109(2):221-7.</citation>
    <PMID>17154394</PMID>
  </reference>
  <reference>
    <citation>Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004 Jun 9;291(22):2705-12.</citation>
    <PMID>15187051</PMID>
  </reference>
  <reference>
    <citation>Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009 Apr;10(4):327-40. doi: 10.1016/S1470-2045(09)70026-9. Epub 2009 Mar 11.</citation>
    <PMID>19282241</PMID>
  </reference>
  <reference>
    <citation>van Nagell JR Jr, DePriest PD, Ueland FR, DeSimone CP, Cooper AL, McDonald JM, Pavlik EJ, Kryscio RJ. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer. 2007 May 1;109(9):1887-96.</citation>
    <PMID>17373668</PMID>
  </reference>
  <reference>
    <citation>Van den Bosch T, Van Schoubroeck D, Domali E, Vergote I, Moerman P, Amant F, Timmerman D. A thin and regular endometrium on ultrasound is very unlikely in patients with endometrial malignancy. Ultrasound Obstet Gynecol. 2007 Jun;29(6):674-9. Review.</citation>
    <PMID>17523157</PMID>
  </reference>
  <reference>
    <citation>Smith-Bindman R, Kerlikowske K, Feldstein VA, Subak L, Scheidler J, Segal M, Brand R, Grady D. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA. 1998 Nov 4;280(17):1510-7.</citation>
    <PMID>9809732</PMID>
  </reference>
  <reference>
    <citation>Tabor A, Watt HC, Wald NJ. Endometrial thickness as a test for endometrial cancer in women with postmenopausal vaginal bleeding. Obstet Gynecol. 2002 Apr;99(4):663-70.</citation>
    <PMID>12039131</PMID>
  </reference>
  <reference>
    <citation>Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005 Aug 6-12;366(9484):491-505. Review.</citation>
    <PMID>16084259</PMID>
  </reference>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2010</study_first_submitted>
  <study_first_submitted_qc>August 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2010</study_first_posted>
  <last_update_submitted>August 8, 2010</last_update_submitted>
  <last_update_submitted_qc>August 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mahesh Shetty, MD/President</name_title>
    <organization>Woman's Cancer Foundation</organization>
  </responsible_party>
  <keyword>neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

